Intravenous acyclovir in acute herpes zoster infection

Area of Science:

• Virology
• Dermatology
• Infectious Diseases

Background:

• Herpes zoster, commonly known as shingles, is a viral infection caused by the reactivation of the varicella-zoster virus.
• Acute herpes zoster can lead to significant pain and dermatological complications.

Purpose of the Study:

• To evaluate the efficacy of intravenous acyclovir in managing acute herpes zoster in immunocompetent adults.
• To assess the impact of acyclovir on rash development, pain, and ocular involvement.

Main Methods:

• A double-blind, randomized controlled trial was conducted.
• Participants received either intravenous acyclovir (5 mg/kg) or a placebo, administered three times daily.
• Outcomes measured included time to new lesion formation, vesicle collapse, full crusting, pain levels, and ocular involvement.

Main Results:

• Acyclovir significantly accelerated rash development, reducing the time for new lesion formation, vesicle collapse, and crusting.
• Patients treated with acyclovir reported less pain at the end of treatment and at three months compared to placebo, though this difference was not statistically significant.
• No significant effect of acyclovir was observed on ocular involvement.

Conclusions:

• Intravenous acyclovir demonstrates efficacy in improving the cutaneous manifestations of acute herpes zoster.
• While acyclovir may offer some pain relief, further research is needed to confirm its statistical significance in pain management.
• Acyclovir does not appear to influence ocular complications associated with herpes zoster.